Tokyo Tape
Sign in
← Fukuda Denshi

Quarterly report · Q2

6960.TEDINET S100S7MX
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥66.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥134.6bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥62.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥14.0bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥11.1bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥14.1bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥25.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥14.3bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥11.8bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥17.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥210.8bnat 2023-09-30Cons.Assets
Total assets¥206.9bnat 2023-03-31Cons.Assets
Total assets¥196.9bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥39.3bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥171.5bnat 2023-09-30Cons.Net assets
Net assets / equity¥163.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥155.1bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥70.5bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥68.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥67.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥64.9bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥63.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥61.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥23.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥4.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14.2bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥6.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥324.322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥208.782023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥571.252022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥268.432022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥174.152022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio81.3%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio78.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio78.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥737m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥881m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥11.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 520
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant6360000000JPY
Noncurrent liabilitiesCurrentQuarterInstant6288000000JPY
LiabilitiesPrior1YearInstant43875000000JPY
LiabilitiesCurrentQuarterInstant39321000000JPY
Capital stockPrior1YearInstant4621000000JPY
Capital stockCurrentQuarterInstant4621000000JPY
Capital surplusPrior1YearInstant21887000000JPY
Capital surplusCurrentQuarterInstant21887000000JPY
Retained earningsPrior1YearInstant154156000000JPY
Retained earningsCurrentQuarterInstant160917000000JPY
Treasury stockPrior1YearInstant-20398000000JPY
Treasury stockCurrentQuarterInstant-20394000000JPY
Shareholders equityPrior1YearInstant160266000000JPY
Shareholders equityCurrentQuarterInstant167031000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant2395000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant3767000000JPY
Foreign currency translation adjustmentPrior1YearInstant198000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant508000000JPY
Remeasurements of defined benefit plansPrior1YearInstant188000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant168000000JPY
Valuation and translation adjustmentsPrior1YearInstant2781000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant4445000000JPY
Net assetsPrior1YearInstant163047000000JPY
Net assetsCurrentQuarterInstant171477000000JPY
Liabilities and net assetsPrior1YearInstant206922000000JPY
Liabilities and net assetsCurrentQuarterInstant210798000000JPY
Net salesPrior1YTDDuration62628000000JPY
Net salesCurrentYTDDuration66541000000JPY
Cost of salesPrior1YTDDuration29708000000JPY
Cost of salesCurrentYTDDuration29533000000JPY
Gross profitPrior1YTDDuration32919000000JPY
Gross profitCurrentYTDDuration37007000000JPY
Selling general and administrative expensesPrior1YTDDuration21849000000JPY
Selling general and administrative expensesCurrentYTDDuration23055000000JPY
Operating incomePrior1YTDDuration11070000000JPY
Operating incomeCurrentYTDDuration13951000000JPY
Interest income noiPrior1YTDDuration30000000JPY
Interest income noiCurrentYTDDuration44000000JPY
Dividends income noiPrior1YTDDuration99000000JPY
Dividends income noiCurrentYTDDuration110000000JPY
Foreign exchange gains noiPrior1YTDDuration386000000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Gain on investments in partnership noiPrior1YTDDuration17000000JPY
Gain on investments in partnership noiCurrentYTDDuration1000000JPY
Other noiPrior1YTDDuration80000000JPY
Other noiCurrentYTDDuration91000000JPY
Non operating incomePrior1YTDDuration614000000JPY
Non operating incomeCurrentYTDDuration247000000JPY
Interest expenses noePrior1YTDDuration17000000JPY
Interest expenses noeCurrentYTDDuration16000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass